Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actinium-225 satoreotide - Ariceum Therapeutics

Next Previous
Drug Profile

Actinium-225 satoreotide - Ariceum Therapeutics

Alternative Names: 225AC- satoreotide; 225AC-SSO110; [225AC] satoreotide - Ariceum Therapeutics; [225Ac]Ac-SSO110; Ac225 satoreotide - Ariceum Therapeutics

Latest Information Update: 14 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ariceum Therapeutics
  • Class Antineoplastics; Drug conjugates; Peptides; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Merkel cell carcinoma; Small cell lung cancer

Most Recent Events

  • 22 Apr 2025 Phase-I/II clinical trials in Merkel cell carcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06939036) (EudraCT2024-515041-42-00)
  • 22 Apr 2025 Phase-I/II clinical trials in Small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06939036) (EudraCT2024-515041-42-00)
  • 06 Feb 2025 Actinium-225 satoreotide - Ariceum Therapeutics receives Orphan Drug status for Small cell lung cancer in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top